Janney Montgomery Scott LLC Acquires 5,753 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janney Montgomery Scott LLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,806 shares of the medical equipment provider’s stock after buying an additional 5,753 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Lantheus were worth $1,772,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Dakota Wealth Management grew its position in shares of Lantheus by 13.4% in the 4th quarter. Dakota Wealth Management now owns 3,468 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 409 shares during the period. UMB Bank n.a. grew its holdings in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the period. Shelton Wealth Management LLC increased its position in Lantheus by 77.8% during the fourth quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock worth $1,071,000 after buying an additional 5,237 shares during the last quarter. Procyon Advisors LLC increased its holdings in shares of Lantheus by 11.1% during the 4th quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock worth $323,000 after acquiring an additional 361 shares during the last quarter. Finally, Empirical Asset Management LLC bought a new position in shares of Lantheus in the fourth quarter valued at about $323,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on LNTH. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Down 0.3 %

NASDAQ:LNTH opened at $92.51 on Monday. Lantheus Holdings, Inc. has a 12 month low of $51.79 and a 12 month high of $126.89. The stock has a market capitalization of $6.43 billion, a price-to-earnings ratio of 15.39 and a beta of 0.46. The firm has a fifty day simple moving average of $92.05 and a two-hundred day simple moving average of $99.52.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.